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bThis review covers the period from July 2010 to June 2011
with one exception.
Aortic Stenosis (AS)
Aortic valve and arterial calcification inversely correlate
with osteoporotic bone remodeling. Using near-infrared
fluorescence molecular imaging agents targeting macro-
phages and osteogenesis, investigators were able to visualize
arterial, valvular, and bone metabolism (1). In apolipopro-
tein E–1– mice with or without renal disease, significant
arterial and aortic valve (AV) calcification was shown to
correlate with the severity of atherosclerosis. Additional
sophisticated studies were performed. The authors concluded:
“This study provides direct in vivo evidence that in arteries and
aortic valves, macrophage burden and calcification associate
with each other, whereas inflammation inversely correlates
with bone mineralization. Thus, understanding inflammatory
signaling mechanisms may offer insight into selective abroga-
tion of divergent calcific phenomena.”
Inflammation is increased in mild and moderately calcified
AV with mild/moderate AS but not in severely calcified
valves with severe AS. Inflammation was assessed with
fluorodeoxyglucose (FDG) positron emission tomography
(PET) imaging in 42 patients with AS and 42 controls (2).
The AV PET signal (target-to-background [TBR]) was
increased compared to controls. Further, TBR was in-
creased in mildly and moderately calcified AV valves (and in
mild and moderately severe AS), but not in severely calcified
valves (and in severe AS) (Fig. 1). Thus, inflammation may
reduce in “late” stage AS. These findings, note the authors,
may have implications in the design of future studies
assessing the effects of agents attempting to modify the
progression of AS.
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2011, accepted March 28, 2012.Abnormal multidirectional myocardial functions in patients
with AS and preserved left ventricular (LV) function.
A total of 420 patients with mild, moderate, and severe AS
(mean age 66.1  14.5 years) had multidirectional strain and
strain rate imaging by 2-dimensional (2D) speckle tracking (3)
unction. Patients were more likely to be older and at a worse
ew York Heart Association (NYHA) functional class (for
oth, p 0.001) with increasing AS severity. The investigators
ound a progressive stepwise impairment in longitudinal, cir-
umferential, and radial strain and strain rate with increas-
ng severity of AS (all p  0.001). The abnormal strain
tarted in the subendocardium in mild AS, progressed to
id-wall with moderate AS, and to transmural dysfunction
ith severe AS.
nappropriately high LV mass is associated with worse
utcomes in asymptomatic patients with severe AS.
nappropriately high LV mass (LV mass exceeding 10% of
xpected value from height, sex, and stroke work) was present in
21 patients with asymptomatic severe AS. Their outcomes were
ompared to 88 patients with asymptomatic severe AS but
ppropriate LV mass (4). Mean age in the study was 75  10
ears. At the end of follow-up (22 13 months), a clinical event
all-cause death, aortic valve replacement, or hospital admission
or nonfatal myocardial infarction and/or heart failure) occurred in
7% of those with inappropriately high LV mass versus 30% in
hose with appropriate LV mass (p  0.001). Subjects with
nappropriate LV mass were older and had lower blood pressure
han those with appropriate LV mass. At 1, 3, and 5 years,
vent-free survival was significantly higher in patients with appro-
riate LV mass compared to those with inappropriate LV mass
all p 0.01). Left ventricular hypertrophy (LVH) was detected
n 75% of the sample. In patients with high LV mass and LVH,
he risk of adverse events was 69% versus 24% in those with LVH
ut normal LV mass (Fig. 2).
COMMENT. In 1988, Carroll et al. (5) described the phe-
nomenon of “excessive hypertrophy,” which also occurred
more commonly in women.
Only changes in severity of AS are predictors of symp-
tomatic deterioration in asymptomatic patients with
moderate or severe AS and normal left ventricular ejection
fraction. A total of 183 patients with moderate or severe AS
(aortic valve area [AVA], mean 0.96 cm2, age median 70
years, and LVEF median 0.74) were followed for a median
of 31 months (6). Patients were followed with clinical
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Year in Valvular Heart Disease July 10, 2012:85–95evaluation at 6-month intervals and had echocardiograms
every 12 months for first 24 to 36 months. During
follow-up, 58% suffered symptomatic deterioration
(including 3 sudden cardiac deaths and 1 resuscitated
cardiac arrest) and higher peak aortic valve velocities.
AVA decrease (0.1 cm2/m2; hazard ratio [HR]: 1.23;
5% confidence interval [CI]: 1.12 to 1.35; p  0.004)
nd aortic velocity increase (0.5 m/s; HR: 1.43; 95% CI:
Figure 1 Fluorodeoxyglucose Uptake Versus AS
(A) Aortic valve fluorodeoxyglucose positron emission tomography signal in aor-
tic stenosis (AS) group (red) is increased (p  0.001) compared with age-
matched, no AS controls (yellow), as assessed by target-to-background ratio
(TBR). (B) TBR is increased in mild (p  0.001) and moderate stenosis (p 
0.001) versus controls and in moderate AS versus severe AS (p  0.01), but
was not significantly different between severe AS and controls. Reprinted,
with permission, from Marincheva-Savcheva et al. (2).
Figure 2 Inappropriate LV Mass Is Associated With Worse Out
In asymptomatic patients with severe aortic stenosis aortic valve area (0.5  0.1
propriately high LV mass (red) compared with those with appropriate LV mass (blu
with LV hypertrophy (B). Reprinted, with permission, from Cioffi et al. (4)..25 to 1.64; p  0.0001) were predictors of symptomatic
eterioration.
COMMENT. Although these “older” patients were followed
carefully at 6-month intervals, there were 3 sudden deaths
and 1 cardiac arrest. There are no data on coronary
arteriography; incidence of diabetes, lipid abnormalities,
and renal dysfunction were not presented.
Fewer women with severe AS are referred for aortic valve
replacement (AVR). From 2004 through 2005, 362 adult
patients with severe AS and class I indication for AVR were
identified at a single institution (7). Of these, 52% were
women. Overall, 72% underwent AVR; in patients who
underwent AVR, Kaplan-Meier survival rates were similar
in women and men. AVR was performed in 64% of women
compared to 81% of men (p  0.001). After adjusting for
multiple covariates, women had 2.1-fold lower odds of
undergoing AVR compared to men (p  0.02). After
matching for age and Society of Thoracic Surgeons (STS)
risk score, women underwent AVR at a 19% lower relative
rate compared to men (p  0.03). Importantly, of patients
with Class I indication for AVR, 83% of men versus 68% of
women (p 0.001) were referred for evaluation by a cardiac
urgeon. Of those referred for cardiac surgical evaluation,
8% of men and 93% of women underwent AVR (p 
.07).
COMMENT. This is an important paper. Hartzell et al. (7)
have presented an excellent study that is comprehensive,
with superior analysis and presentation of the data.
Percutaneous balloon aortic valvuloplasty (PBAP) was
still being performed as a clinical procedure for patients
with severe AS...why? From December 2004 to December
2008, 111 patients (mean age 82 8 years, 56% female) had
s
2) and normal left ventricular ejection fraction (0.58  0.12), those with inap-
ve a worse event-free survival up to 5 years in all patients (A) and subgroupscome
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July 10, 2012:85–95 Year in Valvular Heart DiseasePBAP for severe AS. Compared to patients 80 years of
age, patients 80 years of age had lower left ventricular
ejection fractions (43.5% vs. 1%; p  0.01) and smaller
aortic valve areas (0.59 vs. 0.73 cm2; p  0.01). About 90%
were in NYHA functional class III or IV, 5% were asymp-
tomatic, and 6% were in class II. The majority of patients
(77%) were considered not to be surgical candidates. The
procedure was elective in 22% and emergent in 5%. In the 2
subgroups, the AVA increased to 0.89  0.31 cm2 in the
lder group and 1.02 0.37 cm2 in the younger group (p
.05). Complication rates: 1) composite of vascular compli-
ations at access site was 10.8%; 2) composite of intrapro-
edural complications of intubation, pressor therapy, car-
iopulmonary resuscitation (CPR) and death was 32.4%;
nd 3) composite of in-hospital complications (death, car-
iac arrest, myocardial infarction, tamponade) was 20.7%.
n-hospital mortality was 8.1%.
COMMENT. In 1991, this procedure was shown in a large
National Heart, Lung, and Blood Institute registry to be
ineffective with regard to clinical status and outcome (9).
Other registries also showed it was ineffective and percuta-
neous balloon aortic valvuloplasty was abandoned. The 1998
and 2006 American College of Cardiology/American Heart
Association guidelines for the management of valvular heart
disease gave it a Class III grade for calcified valves. Data on
the indications, clinical benefits of the procedure, on patient
follow-up, and frequency of subsequent AVR were not
presented.
Refusal or denial of AVR in octogenarians with severe
AS results in 2-fold excess mortality in up to 5 years of
follow-up. A total of 163 octogenarians (mean age 84  3
years) with severe AS and an indication for AVR were
entered in an echocardiographic registry (10). The 5-year
survival for the 97 patients who had AVR versus the 66
patients who were treated conservatively was 66% and 31%,
respectively (p  0.001). After adjustment for propensity
score, patients undergoing AVR had a better outcome than
those treated conservatively (HR: 0.56, 95% CI: 0.29 to
0.91, p  0.022).
Aortic Regurgitation (AR)
Good results of aortic valve repair (AVrep) for AR due to
aortic valve-cusp prolapse (AV-CP). A total of 111 pa-
tients with trileaflet valves had AVrep for AV-CP: 50 of
hese patients had AR due to AV-CP (“isolated group”) and
1 also had aortic dilation (“associated group”) (11). On
re-operative echocardiography, the presence of an eccen-
ric aortic insufficiency jet (of any severity) had 92% sensi-
ivity, 96% specificity for the detection of single AV-CP. A
ransverse fibrous band on the prolapsing cusp correctly local-
zed the AV-CP (sensitivity 57%; specificity 92%). At 8 years
f follow-up, AV reoperation was needed in 0% in the isolated
roup versus 7  5% in the “associated” group (p  0.33). At
years, AR (2) was present in 10 5% in the isolated group
ersus 15  8% in the associated group (p  0.54).icuspid Aortic Valve (BAV)
reater loss of aortic medial elastic fibers in ascending
ortic aneurysm with AR than with AS. Of 122 patients
ith ascending aortic aneurysm without aortitis or acute
issection, the AV was congenitally malformed (unicuspid
r bicuspid) in 58 of 59 (98%) of patients with AS and in 38
f 63 (60%) with AR (12). Loss of medial elastic fiber in the
scending aortic aneurysm was 0 to 1 (grading scale 0 to
) in 90% of patients with AS and bicuspid valves. In
hose with “pure” AR, medial elastic fiber loss of 2 to 4
as present in 47% of those with bicuspid valves and in all
3 patients with tricuspid-Marfan syndrome. In an unad-
usted analysis in 96 patients with congenitally malformed
alves, the 38 patients with AR had a higher likelihood of
 to 4 loss of medial elastic fiber (odds ratio [OR]: 8.78;
5% CI: 2.95 to 28.13).
ow risk of aortic events in patients with BAV following
VR. Among 1,286 patients age 58  14 years, the
ndications for AVR were AS (83%), AR (5%), and AS/AR
12%) in patients with ascending aortas of 40 mm. At a
edian of 12 years after AVR (13), the incidence of aortic
issection, ascending aortic aneurysm replacement, and of
rogressive aortic enlargement were 1%, 0.9%, and 9.9%,
espectively.
COMMENT. Does this study provide the clinical implica-
tions for the study of Roberts et al. (12)?
Mitral Regurgitation (MR)
Real-time 3-dimensional transesophageal echocardio-
graphy (RT3D-TEE) provides more accurate mapping of
mitral valve prolapse (MVP) than do 2D imaging and
RT3D transthoracic echocardiography (TTE). In 222
consecutive patients undergoing MV repair for MVP,
RT3D-TEE identified MVP in 204 patients more accu-
rately (92%) than 2D-TEE (78%), RT3D-TTE (80%), and
2D-TTE (54%) (14). In 60 patients with complex MVP
(1 segment localization or commissural lesions), RT3D-
TEE were correctly identified 58 patients (96.5%), com-
pared to 70%, 52%, and 35% detected by 2D-TEE, RT3D-
TTE, and 2D-TTE, respectively (p  0.0001) (Fig. 3).
ultiplanar reconstruction enabled RT3D-TEE to differ-
ntiate dominant (5 mm) displacement and secondary (2-
o 5-mm displacement) in agreement with surgically
ecognized dominant lesions 100% of the time. RT3D-
EE also correctly identified clefts and subclefts in the MV.
COMMENT. This is an important and valuable study. It
provides a major step in the more accurate, and hopefully
more reproducible, assessment of MVP.
Increased left atrial (LA) volume index is associated with
worse outcome? Patients with LA volume 60 ml/m2
determined echocardiographically had a worse outcome
with “medical therapy” than those with smaller LA volumes
(15). Those with regurgitant volume 60 ml/m2 and LA
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Year in Valvular Heart Disease July 10, 2012:85–95index 60 ml/m2 had worse outcome with medical therapy
han with surgery.
COMMENT. The accompanying excellent editorial (16) em-
phasized that there are many causes and mechanisms of
increased LA size. It is also well known that increased LA
size in many disorders other than MR, increased LA size is
associated with worse outcomes. In this study, the authors
did not provide the cause(s) or mechanism(s) for increase of
LA size (volume). It also has similar generic problems to
other previous studies of MR from this group (17).
Studies of pulmonary hypertension (PHTN) in MR.
FREQUENCY AND SIGNIFICANCE OF PHTN IN PATIENTS WITH
MR DUE TO FLAIL LEAFLETS. MIDA (Mitral Regurgitation
nternational Database) is a registry of these patients in 1
.S. and 4 European centers (18). It included 437 patients
een between 1987 and 2004, of whom 102 (23.8%) had
HTN (defined as pulmonary arterial systolic pressure
PASP] 50 mm Hg at rest) determined by Doppler
chocardiography at baseline. Of 427 patients, 153 (35%)
ere NYHA functional classes III to IV; the remainder had
no or minimal symptoms.” History of coronary artery
isease was 8.2%. The aim was to determine the role of
HTN; the main endpoint of the study was “overall
urvival” (i.e., all-cause death), and one of several endpoints
as death due to cardiovascular disease. Follow-up was
.79  2.8 years; 1-year and 5-year survival was 96 
.1% and 81  2%, respectively. There were 101 (23%)
eaths, of which only 72 of 101 (71%) were cardiovas-
ular deaths. MV surgery was performed in 325 (74.4%)
atients at a median time of 1.8 months (IQR: 0.5 to 6.4
onths). Independent predictors of PHTN were age and
eft atrial size (p  0.001). PHTN was associated with a
igher mortality under “medical management” and with
urgical treatment (HR: 2.09, 95% CI: 1.39 to 3.13, p 
.001); the cutoff value of 50 mm Hg was best associated
ith outcome and had a very low sensitivity of 41% and
pecificity of 82%. Following diagnosis, 104 of 437 (24%)
atients presented with heart failure.
COMMENT. This study provides data on a large number of
patients with flail leaflets. However, there are areas of
concern. 1) The PASP could not be determined in 44%
of patients screened for this study. Thus, 437 patients
included in MIDA represent a select population out of 780
patients with flail leaflets, and extrapolation of these data to
all patients with flail leaflets should be done with great care.
2) The study focused on PHTN, and there are a large
number of statistical analyses of PHTN including 40 HRs,
but the clinical value of many these analyses are not
apparent. 3) There were 13 sudden deaths, 38.5% of which
occurred in those who had undergone surgery. Of 101
deaths, 72 were cardiovascular deaths, but were they due to
the MR or to associated disease such as coronary artery
disease (CAD)? The age of these patients was 67.5  11.4
years. There is no data on the incidence of hypertension,
diabetes, lipid abnormalities, or of smoking status orabout their “medical management.” The percentage of
patients who had coronary arteriography is not stated.
The baseline data did not provide incidence of angina, of
previous myocardial infarction, and of myocardial revas-
cularization; the statement of “history of CAD” should be
defined. 4) They did not separate the incidence of NYHA
functional class II from class I that is mildly symptomatic
from the asymptomatic patient. The indications for surgery
Figure 3 3D-TEE Images Compared Mitral Valve Prolapse
The accuracy of diagnosis of simple lesions (A) and complex lesions (B) of
mitral valve prolapse by echocardiography compared with findings at surgery
are shown. The percentage of echocardiographic findings that were confirmed
at surgery are shown in red and those that were not are shown in blue. 2D 
2-dimensional; 3D  3-dimensional; RT  real-time; TEE  transesophageal
echocardiogram; TTE transthoracic echocardiogram. Reprinted, with permis-
sion, from La Canna et al. (14).and the percentage of patients who had MV repair versus
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July 10, 2012:85–95 Year in Valvular Heart Diseasemitral valve replacement (MVR) were not presented. Also,
it is not clear what is meant by patient presented with HF
“following diagnosis.”
PHTN IS A PREDICTOR OF OUTCOME IN ORGANIC MR. A
total of 256 patients age 63 12 years were referred for MV
surgery, 80.3% of whom had “degenerative” MVP. PASP
was50 mmHg in 82 patients (32%) (19). PASP50 mm
Hg was “an independent predictor of overall and cardiovas-
cular mortality after surgery in organic MR.” LA volume
correlated with PASP (r  0.31, p  0.001); receiver-
perating characteristic (ROC) of LA volume of 50 ml/m2
for predicting PASP 50 mm Hg had an area under the
curve of 0.68. ROC for PASP to predict long-term survival
after surgery had an area under the curve of 0.7; threshold of
50 mm Hg had a sensitivity of 61% and specificity of 72%.
The indications for surgery were not presented.
COMMENT. Studies of mitral stenosis and MR from the
1950s to the 1980s indicated that PHTN and LA
hypertension determined with invasive techniques were
associated with poorer outcomes, which were improved
with surgical therapy. Those who improved and had
reduced but persistent PHTN after surgery also had a
poorer outcome. Thus, the importance of PHTN has
been recognized for a long time.
The first method to diagnose PHTN is by physical
examination of the patient; in the early stages, by the
increased intensity of the pulmonary component of the
second heart sound (P2) at rest and, if necessary, by
exercising the patient at the bedside; in the later stages, by
its effects on the right ventricle (RV). Currently, the issue is
the limits of measurement of PHTN by echocardiography-
Doppler. These include the following. 1) In a significant
percent of patients, PASP cannot be estimated. This was so
in 43.9% of patients in MIDA (18) and 40% in the Mayo
Study (20). This potentially would affect the assessment of
the clinical applicability of the observed findings. 2) In
the study of Le Tourneau et al. (19) where PASP was
measured in 38 patients by noninvasive and invasive
methods within 48 h of each other, the r value was 0.74
(Fig. 4), and difference was 7.6  9.6 mm Hg (mean 
2 SD); the Bland-Altman analysis showed a difference of
15 mm Hg for estimated PASP that ranged from 20 to
80 mm Hg and particularly in the PASP range of 40 to
60 mm Hg. 3) A meta-analysis of 29 published studies
(21) and 429 patients showed a modest correlation with
invasively measured PASP even in those with a PASP
threshold of 40 mm Hg. Eight of 29 studies included only
cardiac cases. These authors concluded: 1) echocardiogra-
phy is a useful noninvasive modality for measuring pulmo-
nary pressure; and 2) considering the limitations, “the
diagnosis of pulmonary hypertension and the assessment of
response to therapy requires right heart catheterization.”
The authors of MIDA acknowledged the “reproducibility of
estimation of PASP is more limited than is achievable by
other techniques (specifically right heart catheterization)”(18). Right heart catheterization with measurement of mean
PA, mean PA wedge pressures (indirect LA pressure), and
cardiac output by invasive techniques also allows for deter-
mining the mechanism of PHTN.
Exercise echocardiography. There were 2 publications in
“consecutive” patients by the same group: Study A was
published in the Journal on July 20, 2010 (22), and Study B
was published in Circulation on July 6, 2010 (23) (Table 1).
Tricuspid Regurgitation (TR)
Wide range of mechanical prosthetic heart valve (PHV)
areas “early” after PHV implantation. Prostheses devel-
oped by St. Jude Medical (St. Paul, Minnesota) (n  51),
ardiomedics (Irvine, California) (n  17), and Starr-
dwards (n 10) mechanical prosthetic valves were studied
24). PHV area and index in each valve size overlapped with
hose of other valve sizes for each brand of PHV. The
uthors stated: “Hemodynamic variables were considerably
ess favorable in patients with Starr-Edwards prosthesis.”
COMMENT. This is an interesting and valuable study. Note:
Starr-Edwards PHV sizes 30, 32, and 34 mm were studied
but had data from only 1, 3, and 6 patients, respectively.
Infective Endocarditis (IE)
Point system for predicting mortality/complications of
IE surgery. Using the STS database of 19,543 patients
undergoing IE surgery from 2002 through 2008, a risk
scoring system was developed (25). Overall unadjusted
mortality was 8.2%. The individual points in the system
ranged from 1 to 17. The greater number of points
predicted a higher incidence of complications, which oc-
curred in 53% of patients.
Women have less surgery and worse prognosis than
men. From 2000 through 2008, 271 new cases with IE
were identified at a large university hospital in Barcelona:
183 were men and 88 were women (26). Women were older
than men were (63 16 years vs. 58 18 years, p 0.006)
but had similar comorbidities. When surgery was indicated,
women were less likely to undergo the procedure than were
men (26% vs. 47%, p  0.001) and had higher in-hospital
mortality (32% vs. 23%, p  0.05) and 1-year mortality
(38% vs. 26%, p  0.04). Surgery was a protective factor for
both values of mortality.
Transcatheter Valve Therapy (TVT)
The Valve Academic Research Consortium report presents
standardized endpoint definitions for transcatheter aortic
valve implantation clinical trials (27).
Aortic
Randomized trial: TVT with Sapien valve (Edwards
Lifesciences, Irvine, California) is not inferior to surgical
AVR at 1 year in high-risk patients with severe AS. In
699 high-risk patients, overall mean score of 11.8% on
90 Rahimtoola JACC Vol. 60, No. 2, 2012
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in the TVT group versus the surgical group at 30 days
were 3.4% versus 6.5% (p  0.07), respectively, and at 1
year were 24.2% versus 26.8% (p  0.44) (Fig. 5). The
differences were considered “noninferior” (28). The sta-
tistically significant differences at 30 days and at 1 year
are shown in Table 2. The expected 30-day mortality
from the STS score (11.8%) was much higher than the
mortality in patients who actually had the surgery (8.0%).
In the TVT group, at 30 days, the symptomatic status
and 6-min walking distance was greater; at 1 year, there
was no significant difference between the 2 groups. In the
TVT group, the mean AV gradient was lower (10.2  4.3
mm Hg vs. 11.5  5.4 mm Hg, p  0.008) and AVA was
greater (1.59  0.48 cm2 vs. 1.44  0.47 cm2, p 
0.002); 16 patients in the TVT group had surgical AVR.
The valve sizes of the PHV that were inserted in the 2
groups were not provided.
Figure 4 PASP by Echo-Doppler Versus Invasive Measurement
(A) Pulmonary artery systolic pressure (PASP) by invasive measurement versus by ech
in PASP by Doppler-invasive versus averaged PASP. Reprinted, with permission,
Data Summarized From the 2 Studies of Exercise EchocardiographTable 1 Data Summarized From the 2 Studies of Exercise Echo
Study A*
Goals/aim 1. Determine exercise-induced changes in MR
(PASP)
2. Evaluate their impact on symptom-free su
Patient entry/study entry 74 consecutive asymptomatic patients/NP:
13 excluded, 61 included
Patient characteristics Degenerative MR (flail MV leaflet in 5)
Age 62 14 yrs; men 51%
Exercise duration, min 8.9 2.3 min
Induced PHTN, n Yes (“n” NP)
Follow-up
Months, mean SD 22 13
Developed symptoms 30 (49%)
Conclusions Exercise-induced increases in MR and in PAS
with reduced symptom-free survival up to
(at 24 months, was 26 11% vs. 67 8%
Study not cited B*Table was developed from data in Study A (22) and Study B (23).
Degenerative  mitral valve prolapse; MR  mitral regurgitation; MV  mitral valve; NP  not presenCOMMENT. This is another landmark important random-
ized trial. However, there are several areas of concern. 1) It
was recommended that the patients entered into the
study should have a score of at least 10% on the STS risk
model. However, the determination of operative risk was
made by the surgeons at each of 25 medical centers,
which is a major problem for a randomized trial. The
surgeons estimated the risk was 15%, but the actual risk
was 6.5%. Thus, the surgeons’ estimates were overesti-
mated by about 150%. The overall mean score was 11.8%;
any measure of variability and the range of scores were
not provided. In the PARTNER B (Placement of Aortic
Transcatheter Valves [Cohort B]: Transfemoral TAVI
vs. Medical Management) trial, the variability was 5.8%.
Is it likely that some patients had a risk score of much
10%, which may account partly for the observed lower
mortality, and that not all patients may have been at high
risk? 2) The incidence of major stroke at 1 year was more
ography-Doppler (n  38). (B) Bland-Altman analysis of difference
Le Tourneau et al. (19).
egenerative MRiography in Degenerative MR
Study B*
in PHTN Identify the echocardiographic predictors of exercise PHTN
and the impact on symptoms (in text, labeled
symptom-free survival)
88 consecutive asymptomatic patients/2005–2009:
10 excluded, 78 included
Degenerative MR (flail MV leaflet in 8)
Age 61 13 yrs; men 56%
NP
Yes [36 (46%)]
19 14
38 (49%)
ssociated
nths
Exercise PHTN was associated with “markedly low
2-year symptom-free survival” (35 8% vs. 75 7%)
Aocardi
fromy in Dcard
and
rvival
P are a
30 mo
)ted; PASP  pulmonary artery systolic pressure; PHTN  pulmonary hypertension.
o
t
(
c
c
t
A
C
A
C
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July 10, 2012:85–95 Year in Valvular Heart Diseasethan twice as high in the TVT group than in the surgical
group, which is of serious concern (29). In the author’s
clinical experience, patients and their spouses/nearest
relatives/caregivers are fearful of the patient experiencing
a major stroke. 3) Thirty-eight patients (10.8%) in the
surgical group did not have surgery versus only 4 (1.1%)
in the TVT group, who did not have TVT, and 16 (13%)
in the TVT group, who had surgical AVR. This may bias
the trial. 4) In the STS registry, only 5% of patients with
AS had a risk score 10%. Does this mean that the
findings of this trial may apply to 5% of patients with AS?
TVT is in its early stages. Improvements in the devices,
procedures, and patient selection will occur in the coming
years. Particular attention should be directed to eliminat-
ing, or at least markedly reducing, the incidence of
stroke.
Myocardial injury is common after TVT and has deleterious
effects. In this study, 101 patients had successful TVT;
evidence for myocardial injury was present in 97% trans-
Figure 5 Time-to-Event Curves for Transcatheter and Surgical A
Kaplan-Meier analysis for various events after aortic valve replacement by surgery
The p values were obtained by log-rank test. Reprinted, with permission, from Smifemoral and 100% with transapical procedures as evidenced
by a rise in cardiac troponin T and by creatine kinase-
myocardial band elevation in transfemoral (47%) and
transapical (77%) patients (30). A transapical approach and
baseline renal dysfunction were associated with greater
increases in biomarkers (p 0.01 in both). The relationship
f changes in LVEF to biomarker showed that increases in
he 2 biomarkers was associated with reductions of LVEF
creatine kinase-myocardial band: r  –0.41, p  0.009;
ardiac troponin T: r  –0.46, p  0.003). The increase of
ardiac troponin T was an independent predictor of mor-
ality at 9  10 months of follow-up.
R grade >2 in 40% of patients who had TVT with
oreValve bioprosthesis. A total of 50 patients with severe
S age 80.5  7.9 years had TVT using the Medtronic
oreValve prosthesis (Medtronic, Minneapolis, Minnesota)
31). The predictions of 2 AR were increased with the
increasing angle of the LV outflow tract to the ascending
aorta (OR: 1.24, p 0.001); chance of “significant AR” was
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Year in Valvular Heart Disease July 10, 2012:85–95at a minimum when the depth of the valve (the so-called
“skirt”) was about 10 mm (OR: 1.1, p  0.024).
Mitral
Randomized trial: TVT with MitraClip (MVmc) is less
effective than surgical MV repair) at reducing MR but
had superior safety and similar clinical outcomes. Of 279
patients, ages 67 13 years, with grade 3 or 4MR, 184
were assigned to percutaneous MV repair and 95 to surgical
MV repair or replacement (32). At 30 days, the incidence of
major adverse events in the percutaneous arm was 15%,
compared to 48% for the surgical arm (p  0.001), indicating
percutaneous repair had superior safety. At 12 months, the
rates of primary endpoint for efficacy were 55% for MVmc
versus 73% for surgical intervention, respectively (p  0.007).
he respective components of primary endpoints were: death:
% and 6%; surgery for MV dysfunction: 20% versus 2%; and
rade 3 or 4 MR: 21% and 20%. At 12 months, both
roups had improved LV size, NYHA functional class, and
uality-of-life measures as compared to baseline.
COMMENT. This is a landmark and important randomized
trial.
Beneficial hemodynamics immediately afterMV repair with
the MitraClip. Immediately after successful MitraClip im-
plantation, hemodynamics were determined, with use of a
Swan-Ganz balloon-flotation catheter (Edwards Life-
sciences), while the patients were still under general anes-
thesia (33). TTE was performed before and 24 h after
MitraClip implantation (Table 3).
Healing response of explanted MitraClip devices. Inves-
tigators evaluation 67 explanted devices from 50 patients;
AVR: TVT Versus Surgical at 30 Days and at 1 YearTable 2 AVR: TVT Versus Surgical at 30 Days and at 1 Year
TVT Surgical p Value
30 days
Stroke or TIA 5.5 2.4 0.04
Major stroke — — —
Vascular complication
Any 17.8 3.8 0.001
Major 11.0 3.2 0.001
Major bleeding 9.3 19.5 0.001
New onset AF 8.6 16.0 0.006
Paravalvular AR 12.2 0.9 0.001
1 year
Stroke or TIA 8.3 4.3 0.04
Major stroke 5.1 2.4 0.07
Vascular complication
Any 18.0 4.8 0.001
Major 11.3 3.5 0.001
Major bleeding 14.7 25.7 0.001
New onset AF 12.1 17.1 0.07
Paravalvular AR 6.8 1.9 0.001
Values are %. Adapted from data in Table 2 of Smith et al. (28).
AF  atrial fibrillation; AR  aortic regurgitation; AVR  aortic valve replacement; TIA 
ransient ischemic attack; TVT  transcatheter valve replacement.implant duration was 1 to 1,878 days (34). Explants were Tanalyzed in 4 post-implantation intervals. The authors
concluded: “In all patients, device mechanical integrity was
maintained up to time of explantation. Four phases of
physiological healing were observed: platelet and fibrin
deposition, inflammation, granulation tissue, and finally
fibrous encapsulation. Long-term device fibrous encapsula-
tion with extension over adjacent mitral leaflets and tissue
bridge formation adds structural stability.”
Tricuspid
Melody pulmonary TVT for tricuspid valve implantation.
Fourteen patients had off-label use of the pulmonary TVT in the
tricuspid position (35). All had prior surgery and had persistent
hemodynamic compromise. Median age was 31.5 years (range 8
to 64 years). The valves were competent, and TR was eliminated
as evaluated by RV angiography (Fig. 6) and by echocardiogra-
phy/Doppler. One patient developed heart block. Follow-up was
up to 9 months (median 4 months).
COMMENT. This is an important step (TVT for TR) that
was much needed.
Pulmonary
Pulmonary valve TVT for RV outflow tract dysfunction
in “adults.” A total of 102 patients, median age 21.5 years
(range 16.2 to 30.1 years) had pulmonary TVT with Melody
valves (Medtronic) for right ventricular outflow tract dys-
function (36). The patients had undergone previous cardiac
surgery. In 96 of 102 patients, pre-stenting was performed.
The systolic gradient between RV and PA was reduced from
a median of 37 to 14 mm Hg. The ratio of systolic RV to
systolic aortic pressure was reduced from 62% to 36% (p 
0.0001). Pulmonary regurgitation, assessed by magnetic
resonance imaging, was reduced from a median of 16% to
1% (p  0.0001). Complications included severe compres-
sion of the left coronary artery in 1 patient, who died 2
weeks later; transient complete AV block (n  1); a single
fracture of stent without loss of stent integrity (n  2); and
endocarditis (n  1). The incidence of stent fractures was 5
Beneficial Hemodynamics With MVmcTable 3 Beneficial Hemodynamics With MVmc
Data From Pre-MVmc Post-MVmc p Value
Cardiac catheterization*
Cardiac output, l/min 5.0 2.0 5.7 1.9 0.003
Cardiac index, l/min/m2 2.7 1.0 3.0 1.0 0.0025
Forward stroke volume, ml 57 17 65 18 0.001
SVR, dyn-s/cm2 1,226 481 1,004 442 0.001
LVEDP, mm Hg 11.0 8.6 8.8 6.0 0.016
TTE†
MR grade 3.3 0.7 1.7 0.9 0.001
Regurgitant volume, ml 51.5 20.4 29.8 20 0.001
LVEDV, ml 172 37 158 38 0.001
Values aremean SD. *Obtained immediately after procedure. †Obtained 24 h later and analyzed
in core laboratory at University of California, San Francisco under the skilled and expert directorship
of Elyse Foster, MD. Adapted from Siegal et al. (33).
LVEDP  left ventricular end-diastolic pressure; LVEDV  left ventricular end-diastolic volume;
MR  mitral regurgitation; MVmc  mitral valve MitraClip; SVR  systemic vascular resistance;
TE  transthoracic echocardiography.
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to 390 days).
Prosthetic Heart Valve (PHV)
Randomized trial: larger PHV index with Edwards Perimount
Magna than with Medtronic Mosaic. A total of 108
patients undergoing AVR for AS, AR, or AS/AR were
randomized to the Edwards Perimount Magna bovine
pericardial valve versus Medtronic Mosaic porcine biopros-
thesis (37). There were fewer patients in the labeled valve
sizes 19 and 27. PHV index at 1 (median 12  1.5 months)
and 5 years (median 4.9  0.8 years) are shown in Table 4. LV
mass regression was greater with Perimount Magna than
with the Mosaic at 5 years by 47.4 35 g/m2 versus 44 36.1
g/m2, respectively (p  0.0001).
Excellent results of AVR in octogenarians. Investigators
studied 249 patients, age 84  3 years (range 80 to 95
years), who underwent minimally invasive AVR, 21% of
whom had previous cardiac surgery (38). The STS-
Figure 6 Right Ventricular Angiograms in Severe Tricuspid Reg
Right ventricular angiograms before (A) and after (B) percutaneous transcatheter
Reprinted, with permission, from Roberts et al. (35).
PHV Index at 1 and 5 Years of Follow-UpTable 4 PHV Index at 1 and 5 Years of Follow-Up
Valve Size*
PHV Area Index (cm2/m2)
p ValueMedtronic Mosaic Perimount Magna
21 mm, n  34
1 year 0.83 0.14 0.99 0.21 0.01
5 years 0.67 0.15 0.90 0.15 0.001
23 mm, n  41
1 year 0.98 0.17 1.16 0.21 0.005
5 years 0.77 0.14 1.12 0.28 0.001
25 mm, n  17
1 year 1.00 0.24 1.22 0.18 0.005
5 years 0.77 0.20 1.18 0.23 0.007
Values are mean  SD. *Valve sizes are the labeled valve sizes. Adapted from data of Dalmau
et al. (37).
PHV  prosthetic heart valve.PROM (STS Predicted Risk of Mortality) score was
10.5% (IQR: 7% to 17%), C-index  0.67, p  0.18, and
the modified EuroSCORE (European System for Car-
diac Operative Risk Evaluation) was 11% (IQR: 6% to
14%), C-index  0.527, p  0.74. The observed opera-
tive mortality was 3%. Stroke rate was 4%. The 1-, 5-,
and 10-year survival was 93%, 77%, and 56%, respec-
tively, which was not significantly different from that of
U.S. age- and sex-matched populations.
COMMENT. The C-index is the area under the ROC curve
and quantifies discriminatory ability, with a value of 0.5
indicating random chance and 1.0 indicating perfect dis-
crimination (39). A measure of variability of the values for
survival was not provided. The accompanying commentary
by Moon (40) is superior.
Mechanical prosthesis (MP) versus bioprosthesis (BP). A
total of 5,433 patients undergoing AVR  coronary artery
bypass graft (CABG) from a review of published studies
were studied; a large number of brands of PHV were
included (41). Patient survival at 1, 5, and 10 years was 90%,
78%, and 57%, respectively. Multivariate predictors of
mortality were age in 10-year increments (OR: 1.53, 95%
CI: 1.27 to 1.86, p  0.001), concomitant CABG (OR:
1.35, 95% CI: 1.01 to 1.82, p  0.05), and creatinine in
10-U increments (mmol/l) (OR: 1.05, 95% CI: 1.03 to 1.06,
p  0.001). The crossover point at which life expectancy
with MP and BP was similar was 59 years for both men
(range 56 and 69 years) and women (range 58 and 63 years).
Long-term survival was independently influenced by age,
male sex, and associated CABG. For men ages 50, 55, 60,
65, 70, and 75 years at initial operation, the lifetime
incidence of structural valve disease was 58%, 50%, 40%,
30%, 20%, and 13%, respectively.
ation
y valve implantation for severe tricuspid regurgitation (TR).urgit
MelodCOMMENT. This is an important study.
C
1
2
(
i
n
i
v
A
w
u
1
P
s
e
(
r
d
0
w
s
(
m
s
0
S
u
w
r
a
w
A
h
w
t
t
i
P
N
2
(
V
d
r
s
3
r
s
w
94 Rahimtoola JACC Vol. 60, No. 2, 2012
Year in Valvular Heart Disease July 10, 2012:85–95Survival after valve replacement (AVR/MVR) in patients
with kidney transplantation. Of 1,698,706 patients in the
Renal Data System database, the investigators indentified
1,335 patients with kidney transplantation patients who had
valve replacement between 1991 to 2004 (42). In-hospital
mortality was 14.0% overall, 11.4% for tissue-valve patients,
and 15% for nontissue-valve patients patients (p  0.09).
Two-year survival rates for BP and MP were 61.5% and
59.5%, respectively (p  0.30). Annual morality was about
20%; 8-year mortality was about 80%. The most powerful
predictors of death were age 75 years (HR: 3.76%, 95%
I: 2.62 to 5.39), age 65 to 74 years (HR: 2.11, 95% CI:
.65 to 2.68), AVR  MVR (HR: 1.71, 95% CI: 1.35 to
.16), and end-stage renal disease caused by diabetes
HR: 1.59, 95% CI: 1.28 to 1.98). Of patients undergo-
ng AVR, the causes of death with tissue valves versus
ontissue valves were cardiovascular (32.1% vs. 28.1%),
nfection (11.6% vs. 14.8%), and other/unknown (56.3%
s. 57.1%), p  0.62.
VR: Increasing pre-operative renal dysfunction is associated
ith increasing operative mortality and reduced survival
p to 10 years of follow-up. In this retrospective review,
,512 patients had AVR, and 896 had AVR CABG (43).
atients were classified as normal or with mild, moderate, or
evere renal dysfunction based on glomerular filtration rate
stimated using the Modification of Diet in Renal Diseases
MDRD) formula. In-hospital mortality was increased with
enal dysfunction, from 2.9% for patients with no renal
ysfunction to 15.8% for those with severe dysfunction (p
.001). In patients requiring dialysis, in-hospital mortality
as 17.3%. Compared to the normal group, the OR in the
evere renal dysfunction group for new dialysis was 15.29
p  0.001). For worsening renal dysfunction in the
oderate group, the OR was 2.51 (p  0.01); and for the
evere renal dysfunction group, the OR was 8.82 (p 
.002).
ame-day coronary arteriography in selected patients
ndergoing elective AVR is safe. A total of 1,413 patients
ho underwent AVR with or without CABG were sepa-
ated into 2 propensity-matched groups: 321 with coronary
rteriography on the same day as AVR (group 1) and 321
ho did not have coronary arteriography on the same day as
VR (group 2) (44). Patients who were believed to be at
igher risk for acute kidney injury (AKI) were excluded. AKI
as defined by the criteria of the AKI Network. Six views of
he coronary arteries were obtained using a hand injection
echnique. Severity of renal dysfunction was defined by creat-
nine clearance obtained by the Cockcroft-Gault formula.
atients were not routinely given sodium bicarbonate or
-acetylcysteine. AKI occurred in 23.4% in group 1 and in
2.3% in group 2.
COMMENT. The most common definitions of contrast-
induced AKI is a rise of serum creatinine by 0.5 mg/dl or
a 25% relative rise of serum creatinine at 48 h of contrast
exposure (45). A large number of factors have beenidentified as risk factors for AKI. Major risk factors that
are common include moderate or severe RD, “nothing by
mouth” status, “excessive” diuresis especially in the pre-
vious 24 to 48 h, diabetes, reduced LV function, low
cardiac output, amount of contrast medium injected, and
use of even therapeutic doses of angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers and of
nonsteriodal anti-inflammatory drugs in those with se-
vere abnormalities of the above listed risk factors.
Valve Prosthesis-Patient Mismatch (VP-PM):
Mitral
Severe VP-PM in patients >65 years of age with
bioprosthesis is associated with worse survival. From
1992 to 2008, 765 patients underwent bioprosthetic (42%)
or mechanical (58%) mitral valve replacement; 48% were
older than 65 years of age (46). VP-PM was classified as
severe (PHV area 0.9 cm2/m2) in 107 patients, moderate
(PHV area 0.9 to 1.2 cm2/m2) in 286 patients, and absent
PHV area 1.2 cm2/m2) in 372 patients. More severe
P-PM was 1 of 9 risk factors that were predictive of late
eath on multivariate analysis (p  0.05). For bioprostethic
ecipients older than 65 years of age, survival of those with
evere VP-PM versus moderate or “absent” at 5 years, was
0 7% versus 43 4%, and at 10 years was 0 versus 21 5%,
espectively (p 0.05). For patients withmechanical prostheses,
urvival with severe or moderate versus absent VP-PM at 5 years
as 77 4% versus 82  3%, and at 10 years, it was 62 
6% versus 66  4%, respectively (p  0.08).
COMMENT. This valuable study documents that even in
patients with severe VP-PM, associated comorbid condi-
tions are important factors for late all-cause mortality.
Reprint requests and correspondence: Dr. Shahbudin H. Ra-
himtoola, University of Southern California, 1200 N. State Street/
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